Boehringer Ingelheim is committed to furthering science that benefits the health of patients and their families. Over the years, we have brought a range of successful products from drug discovery to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding $1 billion dollars or have blockbuster potential.
Our well-balanced pipeline shows a substantial number of new molecular entities and a high share of products in late phase development.
Currently, we are researching to address more than 22 chronic conditions and have successfully launched 12 major products in the past decade, with several more therapies in our pipeline. In addition to our commitment to respiratory and cardiovascular health, Boehringer Ingelheim is committed to making advances in diabetes, oncology and other areas.